ENFN

Enfusion, Inc. [ENFN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ENFN Stock Summary

Top 10 Correlated ETFs

ENFN


Top 10 Correlated Stocks

ENFN


In the News

06:00 29 Mar 2024 ENFN

Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024

Finding  undervalued stocks is one of the key elements to making successful investments. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully recognized their “true potential.

12:50 29 Mar 2024 ENFN

Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript

Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript

11:00 29 Mar 2024 ENFN

Enfusion, Inc. (ENFN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Enfusion, Inc. (ENFN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10:46 29 Mar 2024 ENFN

Enfusion, Inc. (ENFN) Lags Q4 Earnings Estimates

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.

01:28 29 Mar 2024 ENFN

Enfusion: Product Is Sticky And Industry Is Huge

I am recommending a buy rating as I see room for ENFN to grow and visible catalysts for growth acceleration. The company provides an end-to-end SaaS solution for investment managers, making it a sticky product with high pricing power. The industry is large and healthy, with ample opportunities for Enfusion to expand its market share.

04:30 29 Mar 2024 ENFN

Enfusion, Inc. (ENFN) Q3 2023 Earnings Call Transcript

Enfusion, Inc. (NYSE:ENFN ) Q3 2023 Results Conference Call November 7, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Elyse Kanner - JPMorgan Parker Lane - Stifel Crispin Love - Piper Sandler Callie Valenti - Goldman Sachs Natalie Howe - Bank of America Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion's Third Quarter 2023 Earnings Conference Call.

02:22 29 Mar 2024 ENFN

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Enfusion's EBITDA expanded by +48% YoY in Q3 2023, which was +6% better than what the market had expected. ENFN's long-term prospects are favorable, taking into account the room for revenue growth and profit margin improvement. I retain a Buy rating for ENFN stock, in consideration of its good recent quarterly results and positive financial outlook.

11:18 29 Mar 2024 ENFN

Enfusion, Inc. (ENFN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Enfusion, Inc. (ENFN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

09:17 29 Mar 2024 ENFN

The 3 Most Undervalued Under-$10 Stocks to Buy in September 2023

Finding undervalued stocks is one of the key strategies for successful investing. Undervalued stocks are those that trade below their intrinsic value, meaning that the market has not fully recognized their “true potential.

02:02 29 Mar 2024 ENFN

Enfusion, Inc. (ENFN) Q2 2023 Earnings Call Transcript

Enfusion, Inc. (NYSE:ENFN ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Iggy Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Kevin McVeigh - Credit Suisse Parker Lane - Stifel James Faucette - Morgan Stanley Callie Valenti - Goldman Sachs Dylan Becker - William Blair Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion Second Quarter 2023 Earnings Conference Call.

ENFN Financial details

Company Rating
Buy
Market Cap
815.3M
Income
7.77M
Revenue
174.54M
Book val./share
0.42
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
1.1K
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
97.48
Forward P/E
44.05
PEG
-6.7
P/S
6.46
P/B
15.25
P/C
33.04
P/FCF
62.4
Quick Ratio
3.45
Current Ratio
3.79
Debt / Equity
0.29
LT Debt / Equity
0.14
-
-
EPS (TTM)
0.07
EPS next Y
0.21
EPS next Q
0.06
EPS this Y
-144.88%
EPS next Y
186.05%
EPS next 5Y
172.48%
EPS last 5Y
-18.53%
Revenue last 5Y
24.21%
Revenue Q/Q
4.8%
EPS Q/Q
-64%
-
-
-
-
SMA20
-
SMA50
-
SMA100
12.5%
Inst Own
36.67%
Inst Trans
0.69%
ROA
8%
ROE
14%
ROC
0.13%
Gross Margin
67%
Oper. Margin
7%
Profit Margin
5%
Payout
-
Shs Outstand
89.87M
Shs Float
45.82M
-
-
-
-
Target Price
-
52W Range
7.37-11.563
52W High
-15.91%
52W Low
+32.14%
RSI
59
Rel Volume
0.84
Avg Volume
399.84K
Volume
336.28K
Perf Week
-0.32%
Perf Month
1.87%
Perf Quarter
2.1%
Perf Half Y
6.57%
-
-
-
-
Beta
0.989
-
-
Volatility
0.06%, 0.39%
Prev Close
0%
Price
9.25
Change
0.11%

ENFN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.921.241.351.761.35
Net income per share
0.20.06-3.4-0.160.05
Operating cash flow per share
0.190.0300.170.19
Free cash flow per share
0.12-0.05-0.10.070.11
Cash per share
0.090.220.780.730.28
Book value per share
-1.84-3.650.670.760.41
Tangible book value per share
-1.84-3.651.171.210.6
Share holders equity per share
-1.84-3.650.670.760.41
Interest debt per share
0.441.560.060.090.13
Market cap
1.27B1.27B1.74B825.75M1.26B
Enterprise value
1.29B1.35B1.67B770.19M1.24B
P/E ratio
100.28312.53-6.16-62.26208.38
Price to sales ratio
21.515.9515.575.497.19
POCF ratio
103.13762.26-5.47K58.3351.28
PFCF ratio
161.12-372.95-208.71132.6584.76
P/B Ratio
-10.77-5.4331.4512.723.39
PTB ratio
-10.77-5.4331.4512.723.39
EV to sales
21.8717.0114.995.127.08
Enterprise value over EBITDA
85.93160.27-6.13-137.0560.16
EV to operating cash flow
104.9813.09-5.27K54.4150.46
EV to free cash flow
163.89-397.82-200.98123.7383.4
Earnings yield
0.010-0.16-0.020
Free cash flow yield
0.01000.010.01
Debt to equity
-0.23-0.4200.110.29
Debt to assets
1.192.5200.060.14
Net debt to EBITDA
1.4510.020.249.89-0.98
Current ratio
22.7111.065.573.44
Interest coverage
19.163.65-60.05-28.977.28
Income quality
0.970.410-1.073.87
Dividend Yield
0.010000
Payout ratio
0.871.14-0.0100
Sales general and administrative to revenue
0.280.451.350.460.37
Research and developement to revenue
0.070.081.370.110.11
Intangibles to total assets
00000
Capex to operating cash flow
-0.36-3.0425.2-0.56-0.4
Capex to revenue
-0.08-0.06-0.07-0.05-0.06
Capex to depreciation
-3.83-2.21-2.02-1.25-1.13
Stock based compensation to revenue
002.590.170.04
Graham number
2.862.287.141.630.66
ROIC
-0.15-0.04-5-0.160.12
Return on tangible assets
0.550.1-2.66-0.110.06
Graham Net
-2-3.90.840.760.19
Working capital
8.1M18.26M81.57M79.43M49.54M
Tangible asset value
-117.88M-233.56M97.44M103.44M77.48M
Net current asset value
-124.91M-243.75M81.03M76.47M38.36M
Invested capital
-0.23-0.4200.110.29
Average receivables
010.58M15.2M22.04M26.96M
Average payables
0463.5K1.51M2.11M1.95M
Average inventory
00.50.53.05M3.05M
Days sales outstanding
55.555.8859.5562.7758.7
Days payables outstanding
9.538.2728.9813.0614.01
Days of inventory on hand
00047.310
Receivables turnover
6.586.536.135.826.22
Payables turnover
38.2944.1312.627.9526.06
Inventory turnover
16.96M031.85M7.710
ROE
-0.11-0.02-5.1-0.20.11
Capex per share
-0.07-0.08-0.1-0.09-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.470.310.330.350.36
Net income per share
0.010.0400.010
Operating cash flow per share
0.090.010.050.090.04
Free cash flow per share
0.07-0.010.030.070.02
Cash per share
0.730.410.210.250.28
Book value per share
0.760.480.370.40.42
Tangible book value per share
1.210.750.560.570.61
Share holders equity per share
0.760.480.370.40.42
Interest debt per share
0.090.110.10.130.12
Market cap
825.75M1.39B1.46B1.15B1.24B
Enterprise value
770.19M1.35B1.44B1.13B1.22B
P/E ratio
261.9874.01579.09156.83497.32
Price to sales ratio
20.3833.9234.125.8526.66
POCF ratio
109.791.5K242.194.72228.03
PFCF ratio
142.99-854.63383.52120.72394.69
P/B Ratio
12.721.8130.2722.623.09
PTB ratio
12.721.8130.2722.623.09
EV to sales
19.0132.9233.7525.5126.23
Enterprise value over EBITDA
247.65206318.47213.95286.93
EV to operating cash flow
102.411.46K239.6293.47224.32
EV to free cash flow
133.37-829.45379.58119.13388.27
Earnings yield
00000
Free cash flow yield
0.01000.010
Debt to equity
0.110.210.270.330.29
Debt to assets
0.060.110.140.160.14
Net debt to EBITDA
-17.86-6.25-3.3-2.87-4.75
Current ratio
5.576.324.333.793.44
Interest coverage
3.243.5000
Income quality
9.540.26.034.558.52
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.370.350.380.380.37
Research and developement to revenue
0.120.110.10.110.13
Intangibles to total assets
00000
Capex to operating cash flow
-0.23-2.76-0.37-0.22-0.42
Capex to revenue
-0.04-0.06-0.05-0.06-0.05
Capex to depreciation
-1.03-1.37-1.07-1.03-1.09
Stock based compensation to revenue
0.1-0.030.060.060.07
Graham number
0.40.620.20.360.21
ROIC
0.010.050.030.030.01
Return on tangible assets
0.010.040.010.020.01
Graham Net
0.760.40.210.190.2
Working capital
79.43M72.94M45.87M45.67M49.54M
Tangible asset value
103.44M99.15M72.24M73.28M77.48M
Net current asset value
76.47M64.3M37.82M33.58M38.36M
Invested capital
0.110.210.270.330.29
Average receivables
27.42M25.11M24.76M25.01M26.46M
Average payables
1.44M1.49M1.08M1.1M1.78M
Average inventory
4.36M5.85M5.28M4.52M2.04M
Days sales outstanding
57.4353.553.0350.4354.34
Days payables outstanding
11.418.735.58.3212.74
Days of inventory on hand
41.3237.8931.4625.310
Receivables turnover
1.571.681.71.781.66
Payables turnover
7.8910.3116.3710.827.06
Inventory turnover
2.182.382.863.560
ROE
0.010.070.010.040.01
Capex per share
-0.02-0.02-0.02-0.02-0.02

ENFN Frequently Asked Questions

What is Enfusion, Inc. stock symbol ?

Enfusion, Inc. is a US stock , located in Chicago of Il and trading under the symbol ENFN

What is Enfusion, Inc. stock quote today ?

Enfusion, Inc. stock price is $9.25 today.

Is Enfusion, Inc. stock public?

Yes, Enfusion, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap